Articles tagged with Cancer Cells
Researchers found that cancer cells with multiple mutations alter cell competition, allowing them to infiltrate and form highly invasive tumors. The study identified a key mechanism, MMP21, which promotes the production of diffusely invasive cancer cells.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
A new study by Cleveland Clinic researchers reveals significant differences in cell communication between breast tissue with and without BRCA1/2 gene mutations. This discovery provides a foundation for personalized medicine approaches to prevent and treat breast cancer in mutation carriers.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
Scientists from Tokyo Medical and Dental University created a synthetic polymer biomaterial that mimics the pancreatic adenocarcinoma microenvironment, enabling them to identify potential therapeutic targets. The study successfully recapitulates the complex interactions between cancer stem cells and their niche.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers at the University of Leicester have received a significant financial boost to advance their cancer treatment research. The team will investigate 'liquid biopsies' to reveal vital clues about cancer genetic makeup, aiming to predict how cancer changes and which treatment works best for individual patients.
Researchers identified a mechanism that fuels cancer cell growth and developed a new strategy to restrict this process. By restricting glucose in lung cancer cells, they found it caused the cells to lose their specialized features, making them more aggressive.
The study found that SPT5 plays an important role in the development of MYC-dependent tumors, with reduced levels leading to significant regression of tumors. The researchers suggest that SPT5 could be a potential target for pharmacological inhibitors to combat cancer.
Researchers used spatial transcriptomics to analyze cancer cells at the edge and center of tumors, finding distinct gene expression patterns that can predict clinical outcomes and response to therapy. These findings hold promise for improving treatment strategies across various cancer types.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
Researchers at Duke University developed an innovative antibody approach to target and kill tumor-promoting molecules found in cancer cells. The study revealed notable reductions in tumor growth and minimal side effects, making it a promising new treatment option for various types of cancer.
New study reveals that microtubule poisons effectively treat cancer by causing abnormal cell division, leading to tumor cell death. The findings contradict decades-long assumptions about the mechanism of action of these drugs.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
A new tool has been developed to rapidly grow cancer-killing white blood cells, called T cells, which could advance the availability of immunotherapy. The bioreactor is 30% faster than current technologies and can be self-contained in a sterile cabinet.
Researchers discovered cancer cells use a force-generating rescue mechanism to stabilise essential cell structures and resist chemotherapy. The study paves the way for developing drugs that target this mechanism to improve cancer therapies.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
Researchers created a 3D printed tumor model using bioprinting and synthetic chips to better understand complex cancers. The model simulates the surrounding environment, addressing limitations of traditional 2D models.
Researchers discovered that targeting TUG1 can control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors. By inhibiting TUG1, the therapy significantly suppressed tumor growth and improved survival rates when combined with standard treatment.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
Researchers identified a 'guard mechanism' controlling protein GPB1 to attack microbes and cancer cells. The study found that disrupting this mechanism can kill pathogens like Toxoplasma and potentially treat cancer.
Researchers at Scripps Research have identified promising cancer drug targets by combining precise genome engineering and protein activity profiling. They used base editing to alter thousands of possible drug targets, then integrated the data with chemical proteomic information to pinpoint hundreds of potential targets.
Rice University bioengineers Jerzy Szablowski and Julea Vlassakis have received the National Institutes of Health Director’s New Innovator Award for their creative research projects on gene expression and cancer interactions. Szablowski is developing noninvasive methods to map gene expression, while Vlassakis is studying complex single...
Researchers at Northwestern University identified a new evolutionarily conserved RNAi-based form of cell death called Death Induced by Survival gene Elimination (DISE), which targets essential survival genes in cancer cells. This mechanism is ancient and effective against all cancers tested.
Researchers have discovered widespread genomic mutations and instability in transmissible cancers found in clams, which may explain their survival for over 200 years. The study highlights the clam's potential as a model for studying cancer evolution and developing novel strategies to block cancer in humans.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Cancer cells exploit enhancer DNA to accelerate tumor growth, according to researchers at the University of Toronto. The study found that specific proteins regulate this process, suggesting potential treatments through FOXA1 or NFIB suppression.
Researchers combined three highly potent cancer drugs in a single prodrug that is activated in tumor cells, resulting in improved efficacy and reduced side effects. The new approach has shown promise as a potential solution to reduce the burden on patients' bodies during cancer treatment.
Scientists from IRB Barcelona have revealed how chromosomal instability activates a signalling pathway known as JAK/STAT, promoting caspase activity and DNA injury. This damage allows cells to escape from the primary tumour, thereby leading to metastasis.
Researchers from the University of Arizona Cancer Center have identified a new method of activating specific molecules to target cancer cells while leaving healthy cells unharmed. The team developed crPROTACs, which allow for the activation and release of proteins only in cancer cells.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
Researchers developed a novel material that self-assembles into micelle structures targeting cancer cell lysosomes, specifically interacting with Cathepsin B. This leads to dysfunctional lysosomes and apoptotic death of cancer cells. The technology promises a new approach to combat drug resistance in cancer treatment.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
A Brown University team developed a hydrogel-based delivery system that balances tumor acidity and increases doxorubicin's effectiveness against cancer cells. Initial lab tests show promising results, paving the way for pre-clinical trials.
Researchers found that beta-blockers can revive exhausted killer T cells, making them better cancer fighters. The study discovered a link between the sympathetic stress response and immune system response to cancer.
A new study by University of Illinois researchers has collected gene expression data in response to mechanical stiffness in tumors, providing insights into the crosstalk between cancer cells and their environment. The study found that colorectal cancer-associated fibroblasts can sense changes in stiffness and adapt, leading to dramatic...
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers at NYU Abu Dhabi have developed acidity-triggered rational membrane peptide-functionalized nanospheres that combine tumor detection and monitoring with potent, light-triggered cancer therapy. These nanospheres enable improved efficacy of phototherapies with minimal systemic toxicity.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Scientists at IISc have developed hybrid nanoparticles that can kill cancer cells using heat and enable their detection using sound waves. The nanoparticles combine the photothermal and oxidative stress properties of gold and copper sulphide, making them a promising approach for early detection and treatment.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
A new study finds that targeting the ORAI1 calcium channel may provide a promising approach to treating oral cancer. The study reveals that activating this channel causes an influx of calcium into cancer cells, leading to increased pain sensitivity.
Researchers at Case Western Reserve University have identified a new function of the key protein LSD1 that leads to cancer and other diseases. They found that degrading LSD1 rather than just short-circuiting its catalytic activity could be more effective in slowing or stopping cancer growth.
Researchers at Gladstone Institutes identified conditions that enable gamma delta T cells to recognize cancer cells by disrupting energy production and causing cellular stress. This insight suggests that therapies manipulating butyrophilin abundance on the surface of cancer cells could boost gamma delta T cell effectiveness.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Scientists have discovered that small fat-filled lipid droplets can indent and puncture a cell's nucleus, leading to elevated DNA damage. This finding has significant implications for various diseases, including cancer.
Researchers developed a new strategy for T-cell-based immunotherapy using aptamers, which directly activates immune cells against cancer cells without genetic modifications. The innovative regulatory circuit establishes an artificial interaction between T cells and cancer cells.
Researchers at Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, showing how prolonged activation of the STING pathway leads to cellular signaling changes that aid cancer's spread. This finding explains why drugs activating STING have been unsuccessful in clinical trials.
Imperial researchers have imaged Piezo1 channels in human cells and organs, revealing their role in regulating blood pressure, respiration, bladder control, and the immune system. This breakthrough could lead to a better understanding of their role in fundamental physiological processes and potentially new drug targets for diseases.
A new nano-sized force sensor developed by Tampere University researchers allows for the measurement of intracellular forces and mechanical strains. This technology has great potential for studying cancer cells and understanding cellular mechanics.
Researchers have discovered that estrogen promotes tumor growth in ERα-negative cancers, such as triple-negative breast cancer. Anti-estrogenic therapies, when combined with immune checkpoint inhibitors, drastically suppress tumor progression in mice models.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
A biomolecule has been engineered to selectively target and remove mucins from cancer cells, reducing tumor growth and increasing survival in lab-grown human cancer cells and mouse studies. This discovery could play a significant role in future therapies for cancer, as mucins are associated with many diseases.
Researchers have developed novel liquid metal nanoparticles that combine photothermal therapy with immunotherapy, demonstrating high specificity and low side effects. The nanoparticles can target and destroy cancer cells while also stimulating the immune system to fight against tumors.